NCBI PubMed Central
open access
Remdesivir from failed Ebola drug to first FDA-approved COVID-19 antiviral: The medico-legal integration.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluating the impact of antiviral post-exposure prophylaxis for health-care workers during ebolavirus outbreaks: a modelling study#445514
- Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)#146254
- Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)#832388
- Perbandingan Keberhasilan Terapi Antivirus Favipiravir dan Remdesivir pada Pasien Covid-19 di RSUD dr. Doris Sylvanus: Comparison the Success of Favipiravir and Remdesivir Antivirus Therapy of Covid-19 Patiens in RSUD Dr. Doris Sylvanus#1003910
- WHO emergency guidance on the use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks,...#632341
Record · ID 399831
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive